Last 12 months
Inside the activity.
11 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 2 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 3 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2025 Filed Jan 3, 2025 21:40 UTC |
Jordt Raymond MChief Business Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,485 | $7.21 | $17,916.85 |
DisclosureSEC source: 0001104659-25-000836 · tm251877-1_4seq1.xml · nonDerivative · entry 2 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,550 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:40 UTC |
Jordt Raymond MChief Business Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000836 · tm251877-1_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:50 UTC |
WEAVER GREGORY LChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-116882 · tm2428121-2_4seq1.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:50 UTC |
WEAVER GREGORY LChief Financial Officer
|
GrantStock Options (option to buy) · Derivative | 225,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001104659-24-116882 · tm2428121-2_4seq1.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock, par value $0.0001 · 225,000 shares Expires 2034-11-11 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:36 UTC |
Pisano WayneDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104443 · tm2425266-7_4seq1.xml · derivative · entry 1 Pisano Wayne · CIK 0001743611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:34 UTC |
GILL JOHNDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104439 · tm2425266d3_4.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:35 UTC |
Hodges PhilipDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104442 · tm2425266-6_4seq1.xml · derivative · entry 1 Hodges Philip · CIK 0001705562 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:35 UTC |
SAYARE MITCHELDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104441 · tm2425266-5_4seq1.xml · derivative · entry 1 SAYARE MITCHEL · CIK 0001201196 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:34 UTC |
Schafer KlausDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104440 · tm2425266-4_4seq1.xml · derivative · entry 1 Schafer Klaus · CIK 0001705904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:33 UTC |
Jorkasky DianeDirector
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104438 · tm2425266-2_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:33 UTC |
Sohn Catherine A.Director
|
GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104437 · tm2425266-1_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 21,750 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · derivative · entry 6 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,350 Underlying: Common Stock, par value $0.0001 · 21,750 shares Expires 2033-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
Exercise / conversionStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · derivative · entry 5 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
SaleCommon Stock, par value $0.0001 | 8,184 | $6.88 | $56,305.92 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 4 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 55,524 F3 · shares: This sale represents shares sold to cover the exercise price. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 21,750 | $2.50 | $54,375.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 63,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
SaleCommon Stock, par value $0.0001 | 7,827 | $6.93 | $54,241.11 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 2 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 41,958 F3 · shares: This sale represents shares sold to cover the exercise price. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC |
Drutz DavidDirector
|
Exercise / conversionCommon Stock, par value $0.0001 | 20,000 | $2.60 | $52,000.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 49,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 17:47 UTC |
Shutterly AndrewActing Chief Financial Officer
|
GrantCommon Stock, par value $0.0001 | 1,259 | $5.41 | $6,811.19 |
DisclosureSEC source: 0001104659-24-084996 · tm2420669-4_4seq1.xml · nonDerivative · entry 1 Shutterly Andrew · CIK 0002028603 · Acting Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,372 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:45 UTC |
Roberts M ScotChief Scientific Officer
|
GrantCommon Stock, par value $0.0001 | 650 | $5.41 | $3,516.50 |
DisclosureSEC source: 0001104659-24-084995 · tm2420669-3_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,310 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:43 UTC |
Jordt Raymond MChief Business Officer
|
GrantCommon Stock, par value $0.0001 | 917 | $5.41 | $4,960.97 |
DisclosureSEC source: 0001104659-24-084993 · tm2420669-2_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,660 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:40 UTC |
Harris Matthew ScottChief Medical Officer
|
GrantCommon Stock, par value $0.0001 | 1,486 | $5.41 | $8,039.26 |
DisclosureSEC source: 0001104659-24-084991 · tm2420669-1_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,119 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,550 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,330 | $9.32 | $21,715.60 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,660 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · derivative · entry 6 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,550 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,332 | $9.32 | $21,734.24 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,633 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · derivative · entry 6 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,900 Underlying: Common Stock, par value $0.0001 · 18,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 8,376 | $9.32 | $78,064.32 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,028 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionCommon Stock, par value $0.0001 | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 1,801 | $9.88 | $17,793.88 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,215 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · derivative · entry 5 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 1,801 | $9.88 | $17,793.88 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,190 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010779 · tm245213-2_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · derivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,545 Underlying: Common Stock, par value $0.0001 · 16,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Tax withholdingCommon Stock, par value $0.0001 | 7,313 | $9.88 | $72,252.44 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,454 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC |
Garg Vipin KDirector · President and CEO
|
Exercise / conversionCommon Stock, par value $0.0001 | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:03 UTC |
Roberts M ScotChief Scientific Officer
|
GrantCommon Stock, par value $0.0001 | 5,860 | $2.69 | $15,763.40 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,850 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:02 UTC |
Jordt Raymond MChief Business Officer
|
GrantCommon Stock, par value $0.0001 | 5,030 | $2.69 | $13,530.70 |
DisclosureSEC source: 0001104659-24-009542 · tm244961-4_4seq1.xml · nonDerivative · entry 1 Jordt Raymond M · CIK 0001960780 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,743 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. F3 · balance_after: The Issuer withheld 2,494 shares to cover taxes associated with the vesting of RSU on January 1, 2024 instead of the 2,503 shares reported as withheld on the individual's Form 4 filed on January 4, 2024. The updated total is reflective of the foregoing correction. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
GrantCommon Stock, par value $0.0001 | 3,257 | $2.69 | $8,761.33 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,825 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:01 UTC |
Garg Vipin KDirector · President and CEO
|
GrantCommon Stock, par value $0.0001 | 7,889 | $2.69 | $21,221.41 |
DisclosureSEC source: 0001104659-24-009539 · tm244961-2_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,222 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:00 UTC |
Eisenstadt Richard IChief Financial Officer
|
GrantCommon Stock, par value $0.0001 | 4,621 | $2.69 | $12,430.49 |
DisclosureSEC source: 0001104659-24-009538 · tm244961-1_4seq1.xml · nonDerivative · entry 3 Eisenstadt Richard I · CIK 0001515806 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,012 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC |
Roberts M ScotChief Scientific Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,709 | $9.80 | $26,548.20 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,990 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC |
Roberts M ScotChief Scientific Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · derivative · entry 4 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Tax withholdingCommon Stock, par value $0.0001 | 2,709 | $9.80 | $26,548.20 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,568 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC |
Harris Matthew ScottChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009540 · tm244961-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.